Buserelin (Suprefact)

A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.

Also Known As:

Suprefact; Bigonist; Buserelin Acetate; HOE-766; Profact; Receptal; Suprecur; Tiloryth; Acetate, Buserelin; HOE 766; HOE766; Luteinizing hormone-releasing factor (pig), 6-(O-(1,1-dimethylethyl)-D-serine)-9-(N-ethyl-L-prolinamide)-10-deglycinamide-

Networked: 486 relevant articles (64 outcomes, 100 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ohlsson, Bodil: 7 articles (04/2016 - 01/2007)
2.	Sand, Elin: 5 articles (04/2016 - 03/2013)
3.	Chin, Kok-Yong: 4 articles (12/2020 - 01/2018)
4.	Ekblad, Eva: 4 articles (04/2016 - 03/2013)
5.	Ima-Nirwana, Soelaiman: 3 articles (12/2020 - 01/2018)
6.	Mohamad, Nur-Vaizura: 3 articles (12/2020 - 01/2018)
7.	Roth, Bodil: 3 articles (12/2015 - 11/2013)
8.	Imai, Atsushi: 2 articles (01/2016 - 05/2002)
9.	Weström, Björn: 2 articles (12/2015 - 12/2014)
10.	Veress, Béla: 2 articles (05/2014 - 01/2007)

Related Diseases

1.	Endometriosis 02/01/1988 - "Intranasal and subcutaneous buserelin were well accepted and equally effective in inhibiting the pituitary-ovarian function, which caused mild menopausal symptoms but an important regression of endometriosis." 01/01/2010 - "The study demonstrated that DNG is as effective as intranasal buserelin acetate in alleviating endometriosis symptoms, and causes less bone mineral density loss, resulting in the use on a commercial basis for endometriosis patients in Japan from 2008. " 03/01/1989 - "Buserelin appears to be safe, well tolerated, and effective in the management of endometriosis and associated complaints." 06/20/1986 - "The clinical findings showed Buserelin to be effective against endometriosis. " 05/01/1992 - "We performed a randomized clinical trial to evaluate the efficacy of intranasal 400 micrograms buserelin three times daily for 6 months versus expectant management in the treatment of infertile women with pelvic endometriosis stage I or II of the revised American Fertility Society classification. "
2.	Prostatic Neoplasms (Prostate Cancer) 11/15/1985 - "Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer." 04/23/1983 - "Buserelin offers an effective treatment of metastatic prostatic cancer without the side effects and cardiovascular risks associated with oestrogen treatment." 01/01/1988 - "Efficacy of buserelin in advanced prostate cancer and comparison with historical controls." 01/01/1989 - "Buserelin treatment of advanced prostatic cancer: a phase II study." 01/01/1988 - "A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer."
3.	Neoplasms (Cancer) 11/01/1990 - "In contrast, buserelin treatment caused highly significant tumor remission. " 08/01/1999 - "A significant reduction of tumor size was observed in both buserelin-treated rats and Ovx rats compared with NT rats (p<0.01). " 07/01/1985 - "Clinical trials with buserelin in patients of reproductive age undergoing treatment for cancer should be encouraged." 07/01/2003 - "Only 100 ng/ml buserelin induced a significant response in the tumor group. " 01/01/2002 - "The combined treatment using buserelin and L-TAM significantly suppressed the tumor growth compared with the treatment using each single agent. "
4.	Precocious Puberty 10/01/1989 - "Buserelin at a dose of 1800 micrograms/day is effective in the treatment of most but not all patients with precocious puberty." 06/01/1984 - "Since a similar analog was shown to be effective in the short term parenteral treatment of idiopathic precocious puberty in girls (10), we used Buserelin both intranasally and sc to treat patients of both sexes with idiopathic and secondary central precocious puberty to test its efficacy, safety, and potential for long term use. " 02/01/1990 - "Buserelin treatment was safe and well accepted, and offers the promise of improved linear growth potential in precocious puberty." 03/01/1990 - "Buserelin represents a first-line treatment of central precocious puberty. " 06/01/1984 - "These results confirm the efficacy and safety of Buserelin by intranasal and sc routes in patients with sexual precocity and indicate a need for long term studies."
5.	Carcinoma (Carcinomatosis) 12/20/1990 - "Buserelin implants in prostate carcinoma are effective for 2 or 3 months, after a single dose of 6.6 or 10 mg buserelin, respectively. " 07/01/1988 - "Buserelin was considered as an effective and safe drug to treat prostatic carcinoma." 09/01/2006 - "We prospectively evaluated 21 men with carcinoma of the prostate who received one implant of 9.45 mg buserelin subcutaneously. " 01/01/1992 - "From August 1986 to August 1990, 116 patients with prostatic carcinoma, advanced disease (stage C-D1 only in patients older than 75 years, or D2) were treated with Buserelin (0.5 mg 3 times/day subcutaneously for 7 days, followed by 0.4 mg 3 times/day intranasally) until progression. " 01/01/1992 - "Buserelin treatment of advanced prostatic carcinoma: prognostic factor analysis."

Related Drugs and Biologics

1.	Gonadotropin-Releasing Hormone (GnRH)
2.	Hormones (Hormone)
3.	Danazol (Azol)
4.	Tamoxifen
5.	Androgens
6.	Nasal Sprays
7.	Testosterone (Sustanon)
8.	Gonadotropins
9.	dienogest
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Orchiectomy (Orchidectomy)
3.	Castration
4.	Subcutaneous Injections
5.	Withholding Treatment